Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure therapy reduced risks of death and hospitalization for patients with obstructive sleep.
Biomea Fusion, Inc. announced initial positive topline data for the first two cohorts of patients with type 2 diabetes mellitus enrolled in the Phase II portion of its ongoing Phase I/II clinical. | March 29, 2023
In Cohort 3, after 4 weeks of once-daily 100 mg dosing with the investigational, oral covalent menin inhibitor, BMF-219, 89% of patients achieved a reduction in A1c, 78% of patients achieved at least. | March 28, 2023